Search research articles
Contact Us
Filters
Showing results (41-50 of 96) with videos related to
Page
of 10
Sort By:
The Journal of Urology
|
April 25, 2020
Reply by Authors
Antoin Douglawi, Adam Calaway, Isamu Tachibana, et al.
Clinical Genitourinary Cancer
|
March 17, 2020
Risk Factors for Acute Kidney Injury During High-dose Chemotherapy and Outcomes for Patients With Relapsed Germ Cell Tumors
Kevin Juan Zhang, Nasser H Hanna, Sandra K Althouse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2018
Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors
Adam C Calaway, Richard S Foster, Nabil Adra, et al.
Cancer
|
July 14, 2021
Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high-dose chemotherapy and peripheral blood stem cell transplantation
Vaibhav Agrawal, Rafat Abonour, Mohammad Abu Zaid, et al.
Clinical Genitourinary Cancer
|
February 3, 2023
Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT)
Fadi Taza, Rafat Abonour, Mohammad Abu Zaid, et al.
The Journal of Urology
|
June 8, 2022
Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor
Jennifer M King, Sandra Althouse, Clint Cary, et al.
Clinical Genitourinary Cancer
|
July 27, 2020
Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter?
Ryan W Speir, Marcelo Panizzutti Barboza, Adam Calaway, et al.
The Journal of Urology
|
July 21, 2021
Percentage of Teratoma in Orchiectomy and Risk of Retroperitoneal Teratoma at the Time of Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors
Adam C Calaway, Sean Q Kern, David Crook, et al.
Clinical Genitourinary Cancer
|
September 6, 2016
A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors
Andrea Necchi, Gregory R Pond, Nicola Nicolai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2022
Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?
Isamu Tachibana, Sean Q Kern, Antoin Douglawi, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 96) with videos related to
Sort By:
Page
of 10
The Journal of Urology
|
April 25, 2020
Reply by Authors
Antoin Douglawi, Adam Calaway, Isamu Tachibana, et al.
Clinical Genitourinary Cancer
|
March 17, 2020
Risk Factors for Acute Kidney Injury During High-dose Chemotherapy and Outcomes for Patients With Relapsed Germ Cell Tumors
Kevin Juan Zhang, Nasser H Hanna, Sandra K Althouse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2018
Risk of Bleomycin-Related Pulmonary Toxicities and Operative Morbidity After Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Good-Risk Germ Cell Tumors
Adam C Calaway, Richard S Foster, Nabil Adra, et al.
Cancer
|
July 14, 2021
Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high-dose chemotherapy and peripheral blood stem cell transplantation
Vaibhav Agrawal, Rafat Abonour, Mohammad Abu Zaid, et al.
Clinical Genitourinary Cancer
|
February 3, 2023
Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT)
Fadi Taza, Rafat Abonour, Mohammad Abu Zaid, et al.
The Journal of Urology
|
June 8, 2022
Surveillance after Complete Response to First-Line Chemotherapy in Patients with Metastatic Nonseminomatous Germ Cell Tumor
Jennifer M King, Sandra Althouse, Clint Cary, et al.
Clinical Genitourinary Cancer
|
July 27, 2020
Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter?
Ryan W Speir, Marcelo Panizzutti Barboza, Adam Calaway, et al.
The Journal of Urology
|
July 21, 2021
Percentage of Teratoma in Orchiectomy and Risk of Retroperitoneal Teratoma at the Time of Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors
Adam C Calaway, Sean Q Kern, David Crook, et al.
Clinical Genitourinary Cancer
|
September 6, 2016
A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors
Andrea Necchi, Gregory R Pond, Nicola Nicolai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2022
Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?
Isamu Tachibana, Sean Q Kern, Antoin Douglawi, et al.
Page
of 10